Skip to main content
. 2020 Aug 19;39(38):6113–6128. doi: 10.1038/s41388-020-01409-6

Fig. 5. YB1 maintains the protein stability of EphA2 by inhibiting the proteasome degradation pathway.

Fig. 5

a The human EphA2 proximal promoter region [−1 to −2 kb upstream of the transcription start site (TSS)] had three Y-Box sequences (CCAAT/ATTGG). b ChIP analysis of YB1 for the EphA2 promoter region in 786-O cells. ChIP assays were performed using anti-IgG and anti-YB1 antibodies. c EphA2 protein accumulation was analyzed after treatment with MG132 in YB1 knockdown 786-O cells. The values indicate protein expression levels relative to GAPDH levels. d After cycloheximide (CHX) treatment, the half-life of EphA2 protein was analyzed in 786-O cells (vector and shYB1). The values indicate protein expression levels relative to GAPDH levels. e EphA2 protein accumulation was analyzed after treatment with MG132 in YB1 knockdown ACHN cells. The values indicate protein expression levels relative to GAPDH levels. f After cycloheximide (CHX) treatment, the half-life of EphA2 protein was analyzed in ACHN cells (vector and shYB1). The values indicate protein expression levels relative to GAPDH levels. g, h Co-IP analysis of ubiquitination modification of EphA2 in 786-O and ACHN cells (vector and shYB1). The values indicate protein expression levels relative to GAPDH levels. (***P < 0.001, **P < 0.01, compared with the corresponding control).